• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Medicus Pharma Ltd.

    5/20/25 3:43:44 PM ET
    $MDCX
    Get the next $MDCX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001671948
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Medicus Pharma Ltd.
    SEC File Number
    001-42408
    Address of Issuer
    300 CONSHOHOCKEN STATE RD.
    SUITE 200
    W. CONSHOHOCKEN
    PENNSYLVANIA
    19428
    Phone
    610-540-7515
    Name of Person for Whose Account the Securities are To Be Sold
    VELOCITY FUND PARTNERS, LP
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Major Shareholders

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Pershing Advisor Solutions
    95 CHRISTOPHER COLUMBUS DR
    JERSEY CITY � NJ � 07399
    11800023067500.001181672105/20/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/29/2023MergerIssuerCheckbox not checked332374209/29/2023Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/20/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Kenneth R. Melani

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MDCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MDCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Smith Andrew Alasdair

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:10:07 PM ET
    $MDCX

    SEC Form 4 filed by Director Rodgers Cathy Mcmorris

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:52 PM ET
    $MDCX

    SEC Form 4 filed by Director Raju Ajay

    4 - Medicus Pharma Ltd. (0001997296) (Issuer)

    12/18/25 4:09:38 PM ET
    $MDCX

    $MDCX
    SEC Filings

    View All

    SEC Form EFFECT filed by Medicus Pharma Ltd.

    EFFECT - Medicus Pharma Ltd. (0001997296) (Filer)

    2/5/26 12:15:17 AM ET
    $MDCX

    SEC Form S-3 filed by Medicus Pharma Ltd.

    S-3 - Medicus Pharma Ltd. (0001997296) (Filer)

    1/30/26 4:31:21 PM ET
    $MDCX

    Amendment: SEC Form SCHEDULE 13G/A filed by Medicus Pharma Ltd.

    SCHEDULE 13G/A - Medicus Pharma Ltd. (0001997296) (Subject)

    1/5/26 8:35:41 PM ET
    $MDCX

    $MDCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

    Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su

    1/22/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

    PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs

    1/20/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

    PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn

    1/12/26 7:30:00 AM ET
    $MDCX

    $MDCX
    Leadership Updates

    Live Leadership Updates

    View All

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MDCX
    Financials

    Live finance-specific insights

    View All

    Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

    Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its su

    1/22/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

    PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. Since its Nasdaq listing, Medicus has remained focused on disciplined execution across its streamlined clinical portfolio, advancing select therapeutic assets through Phase 2 proof-of-concept and purs

    1/20/26 7:30:00 AM ET
    $MDCX

    Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

    PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone (GnRH) antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026, to be held April 22–24 in Las Vegas, Nevada. The Company's accepted abstract: "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodyn

    1/12/26 7:30:00 AM ET
    $MDCX